Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of spironolactone in CAPD patients with hypokalemia
TCTR20200818005Phase 3Completed
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of spironolactone in hypokalemia, end-stage kidney disease (ESKD), sponsored by None. Started Feb 2017; status: completed.
02
Drugs
spironolactone
03
Conditions
hypokalemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20200818005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200818005.